Why is Repatha not doing so good? What can we do?

hank kessler is a Dartmouth grad and will save repatha.

 

Hhhhaaaaaannnnnnnnk iiiiiiiiiiiiiiiisss aaaawe aaaaaaaweeessssssome! He may not even be able to save this dog of a product. It is overpriced with a lot of generic options. Less than $90 in 4th quarter is not good news at all. With the cost of all the studies, sales force, direct to consumer adds, garbage promotional items, useless nurses, ineffective HUB, and so on it is far from a profitable product. I guess that’s why there is widespread panic and pressure being dumped on the sales force to deliver or be gone.

 

This pressure is not deserved! We need a pat on the back instead a kick in the butt. Look at the facts - Repatha has doubled the sales of Praluent with inferior coverage. TO should be grateful we have done this well.

 

I think the once a month dosing will help...plus lets face it statins have many adverse events..

 

It’s a great for patients to have pcsk9 but amgen needs to make net price lower. Even during their 11 billion dollar heyday of Pfizer Lipitor, it had a net price of several thorns dollars a year.

The data amgen has is not supportive of three times that cost. And back then there were no generic alternatives as there is today. Amgen is just arrogant.

They must have drank the same water as Lavar Ball.

 

Hank is pretty awesome. Brutal environment.

 

Why doesn’t it sell.... simple :
- too expensive
- pain in the a&& to get through insurance
- takes way too much time for dr office staff to manage

Amgen in usual fashion will just blame everyone but themselves.

 

Very good point...just common sense. There simply is no value proposition at this point.
Insurance companies have done an effective job of putting the breaks on Pcsk9’s.
Unless Oddyssey outcome data is much better than Fourier (which I doubt) nothing
Will change minus a BIG drop in price.
The crap providers have to go through to get Repatha is mind boggling.

 

that's why they recruit only the "top 1%" according to tool mngr. in my city and why they pay you the big base to figure out how to solve problems that every branded medication goes thru today. Sounds like a bunch of quitters who never had to work to get something in their lives.

 

stay compliant, right?

 

Tool is right...he/she is making lame attempt to blame certain reps for
Hundred of millions of dollars in missed sales projections.

 

How much longer can we milk this? Repatha sales are flat and outcomes aren’t helping one bit. Reps stepping all over each other and all we have to offer are apologies for patients not getting on therapy.

 

jay Ping Chiang with his McKinsey magic will fix this. He will be the savior to Amgen. All we need are more excel models and PowerPoints

 

How about for every pt. that starts on this drug, the get a $100 gift card to McDonalds or BK?